Janssen Pharmaceuticals is giving 340B entities refunds for overcharges on 14 NDCs during the third and fourth quarters of 2019, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.
“The revisions were due to standard restatements of Medicaid pricing data,” the company’s notice said. Janssen is owned by pharmaceutical giant Johnson & Johnson.
Janssen’s refunds are on NDCs of its antipsychotics Invega and Risperdal, blood thinner Xarelto, and Duragesic fentanyl patch.
Kala Pharmaceuticals notified covered entities on HRSA’s website that it is providing refunds for 340B overcharges on its Inveltys eye drops for inflammation and pain after eye surgery. Kala said the repayments are due to pricing data revisions and cover sales from Q1 2019 through Q4 2020.
Some manufacturers have made a point to say in recent similar 340B refund notices that they were not seeking repayment if entities paid them less than the recalculated 340B ceiling prices. Janssen and Kala’s notices are silent on the subject.
